Achieving remission in clinical practice: Lessons from clinical trial data

Clinical and Experimental Rheumatology

Volumn 31, Issue 4, 2013, Pages 621-632

  Bykerk, Vivian P ^a   Keystone, Edward C ^b   Kuriya, Bindee ^b   Larché, Maggie ^c   Thorne, J Carter ^d   Haraoui, Boulos ^e  

^a Hospital for Special Surgery   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biologic response modifiers; Diseasemodifying anti rheumatic drugs; Remission induction; Review; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EARLY RHEUMATOID ARTHRITIS; FUNCTIONAL ASSESSMENT; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; EVIDENCE-BASED MEDICINE; HUMANS; REMISSION INDUCTION;

EID: 84883524718     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
2. KNEVEL R, SCHOELS M, HUIZINGA TW et al.: Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 987-94.
3. St CLAIR EW, van der HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43.
4. KLARESKOG L, van der HEIJDE D, de JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
5. KURIYA B, ARKEMA EV, BYKERK VP, KEYSTONE EC: Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
6. MA MH, SCOTT IC, KINGSLEY GH, SCOTT DL: Remission in Early Rheumatoid Arthritis. J Rheumatol 2010; 37: 1444-53.
7. SMOLEN JS, ALETAHA D, BIJLSMA JW et al.:Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
8. SCHOELS M, KNEVEL R, ALETAHA D et al.: Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69: 638-43.
9. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011; 63: 573-86.
10. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70: 404-13.
11. BOERS MV: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
12. MOTTONEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FINRACo trial group. Lancet 1999; 353: 1568-73.
13. RANTALAIHO V, KORPELA M, HANNONEN P et al.: The good initial response to therapy with a combination of traditional diseasemodifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60: 1222-31.
14. RANTALAIHO V, KORPELA M, LAASONEN L et al.: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: The 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122.
15. PROUDMAN SM, CONAGHAN PG, RICHARDSON C et al.: Treatment of poor-prognosisearly rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809-19.
16. FERRACCIOLI GFG: Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002; 41: 892-8.
17. EMERY P, BREEDVELD FC, HALL S et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
18. EMERY P, BREEDVELD F, van der HD et al.: Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. Arthritis Rheum 2010; 62: 674-82.
19. WESTHOVENS R, ROBLES M, XIMENES AC et al.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68: 1870-7.
20. SMOLEN JS, FLEISCHMANN R, GUERETTE B et al.: Adalimumab plus methotrexate vs. methotrexate monotherapy for early rheumatoid arthritis: 26-week results (first phase) from the 78-week optima study. EULAR 2010.
21. van der HEIJDE D, BREEDVELD FC, KAVANAUGH A et al.: Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010; 37: 2237-46.
22. SMOLEN JS, FLEISCHMANN R, EMERY P et al.: The optima study of methotrexate and adalimumab: 78-weeek outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. EULAR 2011.
23. EMERY P, KVIEN TK, COMBE B et al.: Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012; 71: 989-92.
24. WELLS AF, WESTHOVENS R, REED DM et al.: Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol 2011; 38: 2362-8.
25. BATHON J, ROBLES M, XIMENES AC, NAYIAGER S et al.: Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011; 70: 1949-56.
26. YAZICI Y, MONIZ RD, KLEM C, ROSENBLATT L, WU G, KREMER JM: Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol 2011; 29: 494-9.
27. TAK PP, RIGBY WF, RUBBERT-ROTH A et al.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39-46.
28. VERSTAPPEN SM, JACOBS JW, van der VEEN MJ et al.: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66: 1443-9.
29. BAKKER MF, JACOBS JW, WELSING PM et al.: Early clinical response to treatment predicts 5-year outcome in RA patients: followup results from the CAMERA study. Ann Rheum Dis 2011; 70: 1099-103.
30. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364: 263-9.
31. GOEKOOP-RUITERMAN YP, VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
32. GOEKOOP-RUITERMAN YPM, De VRIESBOUWSTRA JK, KERSTENS PJSM et al.: DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 2010; 69: 65-9.
33. KLARENBEEK NB, GULER-YUKSEL M, van DER KOOIJ SM et al.: The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011; 70: 1039-46.
34. KLARENBEEK NB, van der KOOIJ SM, GULER-YUKSEL M et al.: Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70: 315-9.
35. DIRVEN L, van den BROEK M, KLARENBEEK NB et al.: Seven year results of DAS steered treatment in the BeST study; clinical and radiological outcomes. ACR 2010. 2010.
36. VAN DER KOOIJ SM, le CESSIE S, GOEKOOPRUITERMAN YP et al.: Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1153-8.
37. ALETAHA D, WARD MM, MACHOLD KP, NELL VP, STAMM T, SMOLEN JS: Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 2625-36.
38. BROWN AK, QUINN MA, KARIM Z et al.: Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 3761-73.
39. BROWN AK, CONAGHAN PG, KARIM Z et al.: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-67.
40. SALEEM B, BROWN AK, KEEN H et al.: Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with diseasemodifying antirheumatic drugs: A clinical and imaging comparative study. Arthritis Rheum 2009; 60: 1915-22.
41. STUDENIC P, SMOLEN JS, ALETAHA D: Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. Ann Rheum Dis 2012; 71: 1702-5.
42. KURIYA B, SUN Y, BOIRE G et al.: Remission in Early Rheumatoid Arthritis --A Comparison of New ACR/EULAR Remission Criteria to Established Criteria. J Rheumatol 2012; 39: 1155-8.
43. KHANNA D, OH M, FURST DE et al.: Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum 2007; 57: 440-7.
44. KLARENBEEK NB, KOEVOETS R, van der HEIJDE DM et al.: Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1815-21.
45. SALEEM B, BROWN AK, KEEN H et al.: Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis 2011; 70: 792-8.
46. LILLEGRAVEN S, PRINCE FH, SHADICK NA et al.: Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis 2012; 71: 681-6.
47. BOMBARDIER C, AKHAVAN P, CHEN M, LI X: Sustaned remission in early RA: results from SONORA study. ACR 2010.
48. JAYAKUMAR K, NORTON S, DIXEY J et al.: Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 2012; 51: 169-75.
49. van der WOUDE D, YOUNG A, BRAND R et al.: Prevalence and predictive factors for DMARD-free remission in RA: Lessons from two large early arthritiscohorts. 2008 ACR Annual Meeting. 2008.
50. KURIYA B, HARAOUI B, BOIRE G et al.: Age, sex, RF antibodies, baseline HAQ and DAS28 score -but not the type of initial treakment -are predictive of clinical remission at 1 year in early inflammatory arthritis. ACR 2010.
51. WEVERS-DE BK, VISSER K, HEIMANS L et al.: Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Ann Rheum Dis 2012; 71: 1472-7.
52. ICHIKAWA Y, SAITO T, YAMANAKA H et al.: Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 2010; 37: 723-9.
53. FORSLIND K, AHLMEN M, EBERHARDT K, HAFSTROM I, SVENSSON B: Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 1090-5.
54. VRIES-BOUWSTRA JK, GOEKOOP-RUITERMAN YP, VERPOORT KN et al.: Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58: 1293-8.
55. QUINN MA, GOUGH AK, GREEN MJ et al.: Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45: 478-80.
56. MUSTILA A, KORPELA M, HAAPALA AM et al.: Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol 2011; 29: 500-5.
57. FARRAGHER TM, LUNT M, PLANT D, BUNN DK, BARTON A, SYMMONS DP: Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken) 2010; 62: 664-75.
58. KATCHAMART W, JOHNSON S, LIN HJ, PHUMETHUM V, SALLIOT C, BOMBARDIER C: Predictors for remission in rheumatoid arthritis patients: A Systematic review. Arthritis Care Res (Hoboken) 2010; 62: 1128-43.
59. El MIEDANY Y, YOUSSEF S, MEHANNA AN, El GAAFARY M: Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. Joint Bone Spine 2008; 75: 155-62.
60. van der LINDEN MP, van der WD, IOANFACSINAY A et al.: Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum 2009; 60: 2232-41.
61. KRAUSE D, RAU R, BRAUN J: Glucocorticoid treatment in early rheumatoid arthritis. Clin Exp Rheumatol 2011; 29 (Suppl. 68): S121-S125.
62. BAKKER MF, JACOBS JWG, WELSING PMJ et al.: Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Int Med 2012; 156: 329-39.
63. WASSENBERG S, RAU R, ZEIDLER H: A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis -the Low-Dose Prednisolone Trial. Clin Exp Rheumatol 2011; 29 (Suppl. 68):S68-S72.
64. KLARENBEEK NB, KOEVOETS R, VAN DER HEIJDE DM et al.: Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis 2011; 70: 1815-21.
65. KIEVIT W, FRANSEN J, De WAAL MALEFIJT M et al.: Major improvements in outcomes of Rheumatoid Arthritis since the biologic era and beyond: An historical overview from 1989 until 2008 in a large inception cohort of RA patients. ACR 2010.
66. ALETAHA D, NEOGI T, SILMAN A et al.: Rheumatoid Arthritis Classification Criteria. Arthritis Rheum 2010; 62: 2569-81.
67. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P et al.: Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67: 815-22.
68. HETLAND ML, STENGAARD-PEDERSEN K, JUNKER P et al.: Radiographic progression and remission rates in early rheumatoid arthritis -MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 2010; 69: 1789-95.
69. EMERY P, FLEISCHMANN RM, MORELAND L et al.: A new human anti-TNF-ALPHA monoclonal antiboy administered subcutaneously (SC) every 4 weeks in methotrexate-naive patients with active pheumatoid arthritis (RA); A randomized, double-blind, placebocontrolled, go-before study. Ann Rheum Dis 2008; 67 (Suppl. II): 179.
70. QUINN MA, CONAGHAN PG, O'CONNOR PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 27-35.
71. DUREZ P, MALGHEM J, NZEUSSEU TA et al.: Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007; 56: 3919-27.
72. van TUYL LH, LEMS WF, VOSKUYL AE et al.: Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008; 67: 1574-7.
73. van EIJK IC, NIELEN MM, van DH-B I et al.: Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford) 2012; 51: 686-94.
74. SOUBRIER M, PUECHAL X, SIBILIA J et al.: Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology (Oxford) 2009; 48: 1429-34.
75. JAYAKUMAR K, NORTON S, DIXEY J et al.: Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 2012; 51: 169-75.